Bispecific monoclonal antibody

Atreca and Xencor Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies

Retrieved on: 
Wednesday, July 8, 2020
Medical specialties, Medicine, Immunology, Monoclonal antibodies, Immune system, T cells, Bispecific monoclonal antibody, Antibody, CD3, Solitomab, Bi-specific T-cell engager, Medical specialties, Medicine, Immunology, Monoclonal antibodies, Immune system, T cells, Bispecific monoclonal antibody, Antibody, CD3, Solitomab, Bi-specific T-cell engager, Medical specialties, Medicine, Immunology, Monoclonal antibodies, Immune system, T cells, Bispecific monoclonal antibody, Antibody, CD3, Solitomab, Bi-specific T-cell engager

Atreca will provide antibodies against novel tumor targets from which Xencor will engineer XmAb bispecific antibodies that also bind to the CD3 receptor on T cells.

Key Points: 
  • Atreca will provide antibodies against novel tumor targets from which Xencor will engineer XmAb bispecific antibodies that also bind to the CD3 receptor on T cells.
  • Atreca and Xencor began working together in 2019 under a material transfer agreement to accelerate this new collaboration agreement.
  • Atrecas unique discovery platform complements our protein engineering capabilities and bispecific platform by providing novel, tumor-selective antibodies and targets to engage with cytotoxic T cell killing.
  • This collaboration offers both Xencor and Atreca with several opportunities to advance novel first-in-class CD3 bispecific antibodies for the potential treatment of patients with cancer.

Xencor and Atreca Enter Strategic Collaboration to Discover, Develop and Commercialize Novel T Cell Engaging Bispecific Antibodies

Retrieved on: 
Wednesday, July 8, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Medical specialties, Medicine, Immunology, Monoclonal antibodies, Immune system, T cells, Bispecific monoclonal antibody, Antibody, CD3, Solitomab, Bi-specific T-cell engager, XmAb® Bispecific Fc Technology and CD3 Bispecific Antibodies, Xencor, Inc., Atreca, Inc.

Atreca will provide antibodies against novel tumor targets from which Xencor will engineer XmAb bispecific antibodies that also bind to the CD3 receptor on T cells.

Key Points: 
  • Atreca will provide antibodies against novel tumor targets from which Xencor will engineer XmAb bispecific antibodies that also bind to the CD3 receptor on T cells.
  • Atreca and Xencor began working together in 2019 under a material transfer agreement to accelerate this new collaboration agreement.
  • Atrecas unique discovery platform complements our protein engineering capabilities and bispecific platform by providing novel, tumor-selective antibodies and targets to engage with cytotoxic T cell killing.
  • This collaboration offers both Xencor and Atreca with several opportunities to advance novel first-in-class CD3 bispecific antibodies for the potential treatment of patients with cancer.

F-star Therapeutics Presents Data on FS222 at 2020 AACR Annual Meeting

Retrieved on: 
Monday, June 22, 2020
Biotechnology, Pharmaceutical, Health, Clinical trials, Medical specialties, Medicine, Immunology, Monoclonal antibodies, Immune system, CD137, Oncology, Bispecific monoclonal antibody, Antibody, PD-L1

The preclinical data presented in the poster session show that FS222 simultaneously binds PD-L1 and multimeric CD137 with sub-nanomolar affinity resulting in potent T cell activation, superior to a combination of monoclonal antibodies.

Key Points: 
  • The preclinical data presented in the poster session show that FS222 simultaneously binds PD-L1 and multimeric CD137 with sub-nanomolar affinity resulting in potent T cell activation, superior to a combination of monoclonal antibodies.
  • These data also show that the bispecific antibodys tetravalency enhances its activity by providing optimal PD-L1 blockade, as well as potent CD137 agonism, resulting in significant T cell activation.
  • Furthermore, data from a non-human primate dose-range finding study, also included in the poster, show little evident toxicity upon repeated dosing with FS222.
  • Through its proprietary tetravalent, bispecific antibody (mAb) format, F-star is generating first- and best-in-class drug candidates with monoclonal antibody-like manufacturability.

Xencor Presents Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II

Retrieved on: 
Monday, June 22, 2020
Research, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Medical specialties, Medicine, Immunology, Monoclonal antibodies, Immune system, Bispecific monoclonal antibody, Antibody, Cytokine-induced killer cell

Poster presentations and audio descriptions are available to registrants of the AACR Virtual Annual Meeting .

Key Points: 
  • Poster presentations and audio descriptions are available to registrants of the AACR Virtual Annual Meeting .
  • This selectivity and potency tuning of T-cell activation may provide for higher efficacy and tolerability compared to other bispecific antibody formats.
  • "We have also presented data from our IL-12-Fc cytokine program, which builds off of our prior work with IL-15 and IL-2.
  • Additional data presented on XmAb 2+1 PSMA x CD3 bispecific antibody candidates and XmAb30819, a first-in-class XmAb 2+1 ENPP3 x CD3 bispecific antibody, demonstrated strong reversal of tumor growth in human-cell engrafted mouse models of disease.

EpimAb Biotherapeutics Presents Preclinical Data Characterizing EMB-01 at AACR Virtual Annual Meeting II

Retrieved on: 
Monday, June 22, 2020
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Medical specialties, Monoclonal antibodies, Medicine, Branches of biology, Immunology, Biotechnology, Immune system, Epidermal growth factor receptor, Bispecific monoclonal antibody

EpimAb Biotherapeutics , an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, today presented preclinical data at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II.

Key Points: 
  • EpimAb Biotherapeutics , an emerging Shanghai-based biopharmaceutical company specializing in bispecific antibodies, today presented preclinical data at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II.
  • EMB-01 is currently progressing through a Phase I/II clinical trial in patients with advanced metastatic solid tumors.
  • EMB-01 is a novel bispecific antibody developed based on EpimAbs proprietary FIT-Ig platform to simultaneously target EGFR and cMet on tumor cells.
  • EpimAb is also committed to diversifying its pipeline through selective licensing of its platform and pipeline assets to partners worldwide.

Phanes Therapeutics reveals a new bispecific antibody technology platform at BIO Digital 2020

Retrieved on: 
Tuesday, June 16, 2020
Medical specialties, Medicine, Branches of biology, Immunology, Monoclonal antibodies, Glycoproteins, Antibodies, Immune system, Bispecific monoclonal antibody, Cancer immunotherapy, Immunoglobulin G, Fcab

SAN DIEGO, June 16, 2020 /PRNewswire/ --Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research in immuno-oncology announced today that it has developed a proprietary bispecific antibody technology platform, PACbodyTM, which enables construction of a bispecific antibody using any pair of monoclonal antibodies (mAbs) while maintaining the IgG-like structure.

Key Points: 
  • SAN DIEGO, June 16, 2020 /PRNewswire/ --Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research in immuno-oncology announced today that it has developed a proprietary bispecific antibody technology platform, PACbodyTM, which enables construction of a bispecific antibody using any pair of monoclonal antibodies (mAbs) while maintaining the IgG-like structure.
  • The technology was presented at the BIO Digital 2020.
  • "The beauty of the PACbodyTM bispecific antibody platform is that it's a 'plug and play' technology to quickly make an IgG-like bispecific antibody the native structure of both arms of the bispecific antibody is maintained," said Dr. Hui Zou, PhD, Chief Scientific Officer (CSO) of Phanes Therapeutics.
  • In addition, we'd like to leverage our PACbodyTM technology to help advance the innovation of other players in the industry."

I-Mab and ABL Bio to Present Preclinical Data for Joint Bispecific Antibody Program at the 2020 American Association for Cancer Research Virtual Meeting II

Retrieved on: 
Friday, June 12, 2020
Medical specialties, Immunology, Medicine, Monoclonal antibodies, Bispecific monoclonal antibody, Antibody, CLDN18

TJ-CD4B, also known as ABL111, is a Claudin 18.2 and 4-1BB bispecific antibody jointly developed with South Korea-based ABL Bio, Inc. (Kosdaq: 298380, hereafter "ABL").

Key Points: 
  • TJ-CD4B, also known as ABL111, is a Claudin 18.2 and 4-1BB bispecific antibody jointly developed with South Korea-based ABL Bio, Inc. (Kosdaq: 298380, hereafter "ABL").
  • TJ-CD4B is from I-Mab's emerging bispecific antibody portfolio designed to create novel drug molecules that synergize two pathways for better clinical efficacy.
  • By linking with an antibody against Claudin 18.2, a gastric- and pancreatic-specific cancer antigen, TJ-CD4B/ABL111 is uniquely structured to supercharge T cells in a Claudin 18.2-dependent manner, enhancing anti-tumor immunity while potentially minimizing toxicity.
  • I-Mab plans to advance more novel bispecific antibodies towards clinical development stage, following the lead of TJ-CD4B/ABL111.

Alphamab Oncology and Sanofi Enter Collaboration on KN026 in HER2+ Breast Cancer

Retrieved on: 
Tuesday, June 9, 2020
RTT, Medicine, Clinical medicine, Health, Docetaxel, Sanofi, Breast cancer, HER2/neu, Cancer, Prostate cancer, Bispecific monoclonal antibody

It is used to treat breast cancer, lung cancer, prostate cancer, gastric cancer.

Key Points: 
  • It is used to treat breast cancer, lung cancer, prostate cancer, gastric cancer.
  • Under terms of the agreement, Jiangsu Alphamab and Sanofi will collaborate to evaluate the combination of KN026 and Taxotere (Docetaxel) for HER2+ breast cancer.
  • KN026 is an anti-HER2 bispecific antibody developed by Alphamab Oncology using the proprietary Fc-based heterodimer bispecific platform technology called CRIB (Charge Repulsion Induced Bispecific).
  • For more information, please visit www.sanofi.cn or subscribe to the Sanofi China official WeChat account: SanofiChina and LinkedIn account: Sanofi.

Innovent and Roche Enter into A Strategic Collaboration to Discover and Develop Multiple Products including Cellular Therapies and Bispecific Antibodies

Retrieved on: 
Tuesday, June 9, 2020
Medical specialties, Medicine, Branches of biology, Immunology, Monoclonal antibodies, Antibody, Glycoproteins, Bispecific monoclonal antibody

The collaboration will focus on the discovery, clinical development and commercialization of bispecific antibodies and multiple cell therapies and will be directed to the treatment of hematological and solid cancers.

Key Points: 
  • The collaboration will focus on the discovery, clinical development and commercialization of bispecific antibodies and multiple cell therapies and will be directed to the treatment of hematological and solid cancers.
  • Innovent will create, develop, manufacture, and commercialize the products.
  • Since its inception, Innovent has developed a fully-integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities.
  • Innovent has built an international team of advancedtalents in high-end biological drug development and commercialization, including many overseas experts.

Gritstone Oncology Adopts Genedata Biopharma Platform to Accelerate Development of TCR and Bispecific Antibody Therapeutics

Retrieved on: 
Tuesday, May 26, 2020
Medical specialties, Life sciences, Health, Immunology, Monoclonal antibodies, Biotechnology, Antibody, Glycoproteins, Biopharmaceutical, Genedata, Bispecific monoclonal antibody, Monoclonal antibody therapy

For instance, we anticipate that the platform will be able to handle our bispecific engineering and TCR discovery and optimization workflows without any customization," said Jonah Rainey, Ph.D., Head of Antibody Therapeutics at Gritstone Oncology.

Key Points: 
  • For instance, we anticipate that the platform will be able to handle our bispecific engineering and TCR discovery and optimization workflows without any customization," said Jonah Rainey, Ph.D., Head of Antibody Therapeutics at Gritstone Oncology.
  • Gritstone Oncology will use Genedata Biologics, a purpose-built enterprise platform for biopharma R&D, to design, engineer, and validate next-generation antibody therapeutic molecules such as bispecific antibodies.
  • Using the platform, Gritstone will automate R&D workflows, including molecular biology, screening, engineering, cloning, expression, purification, and analytics processes.
  • "The Genedata Biopharma Platform is a game changer in biopharma R&D.